Find and Pitch Jounalists, Get Your Story Covered

Tags: MDMA ecstasy PTSD therapy care continuum communication

	Profile	Recent Articles on Subject
1	Ed Silverman STAT News Pharmalot columnist. Senior writer at STATnews. pharmaceutical industry	STAT+: Teva fined $503 million for disparaging a rival and using patents to thwart competition - 14 days ago STAT+: Pharmalittle: We’re reading about FTC scrutiny of a Novo deal, a Genentech reorganization, and more - 3 months ago STAT+: U.S. Patent Office software mistakes extend patent life for drugs and need to be fixed, researchers say - 4 months ago STAT+: A Senate bill was touted as a cure for ‘patent thickets.’ Some say the drug industry watered it down - 4 months ago STAT+: Biden administration appeals jury finding in battle over patents for HIV prevention pills - 4 months ago STAT+: Pharmalittle: We’re reading about Sanders dogging Novo Nordisk, Teva patents, and more - 5 months ago STAT+: Biden administration urged to license prostate cancer drug patents in a bid to lower its cost - 7 months ago STAT+: Pharmalittle: We’re reading about Biocon eyeing weight loss drugs, Sanofi layoffs, and more - 7 months ago STAT+: FDA agrees to review a rare disease drug that its developer was about to give up on - 7 months ago STAT+: Pharmalittle: We’re reading about Boehringer biosimilar frustrations, FTC warnings, and more - 7 months ago STAT+: Pharmalittle: We’re reading about Amgen suing Colorado over drug price caps, abortion pills, and more - 8 months ago STAT+: WTO proposal for Covid diagnostics and therapeutics waiver is abandoned - 8 months ago STAT+: Pharmalittle: We’re reading about a nixed Medicare negotiation lawsuit, an Obamacare challenge, and more - 9 months ago STAT+: Pharmalittle: We’re reading about state moves on drug pricing, an asthma med for kids and more - 9 months ago STAT+: A lawsuit over a controversial Sanofi drug shortage is unexpectedly revived - 9 months ago STAT+: Pharmalittle: We’re reading about a tossed PhRMA lawsuit, secrecy clauses, and more - 9 months ago STAT+: Diabetes treatments have improperly listed patents that should be removed, analysis finds - 9 months ago STAT+: Klobuchar urges drugmakers to remove patents FTC calls improper and inaccurate - 10 months ago STAT+: New congressional bill would thwart patent thickets in order to speed generic drugs to market - 10 months ago STAT+: Pharmalittle: We’re reading about Lilly selling drugs directly, UCB leaving BIO, and more news - 10 months ago STAT+: Pharmalittle: FDA approvals rebound, abortion pill orders rise, and more news - 11 months ago STAT+: Pharmalittle: Drugmakers raise prices, pharmacies fear fees, McKinsey settles - 11 months ago STAT+: Patent thickets and terminal disclaimers: How pharma blocks biosimilars from the marketplace - 11 months ago STAT+: Pharmalittle: Curevac loses key patent in battle with BioNTech; Abernethy to step down as Verily CMO - 11 months ago STAT+: Pharmalittle: Bluebird claims big insurer will cover its sickle cell therapy; House Republicans threaten to subpoena FDA commish - 11 months ago STAT+: Pharmalittle: U.S. to impose inflation penalties on dozens of drugmakers; Supreme Court will decide abortion pill access - 11 months ago STAT+: Pharmalittle: Sanofi scraps rare-disease drug deal under FTC pressure; patients regain weight after stopping Lilly’s Zepbound - 11 months ago STAT+: Sanofi ends deal for a rare disease drug after FTC voices monopoly concerns - 11 months ago STAT+: Pharmalittle: Biden pharma patent proposal spurs fears; Klobuchar questions company behind price spike of lead poisoning antidote - 11 months ago STAT+: Biden proposal targeting pharma patents spurs industry fears and consumer doubts - 11 months ago STAT+: Pharmalittle: White House takes aim at pharma patents to lower drug prices; Sanofi CEO defends reducing earnings forecast - 11 months ago STAT+: ‘Learning each other’s language’: FDA, patent office seek to work together to lower drug prices - 11 months ago Most drugmakers have so far ignored looming FTC deadline to withdraw or amend wayward patents - 11 months ago STAT+: Vertex pushes a donation program to widen access to cystic fibrosis treatments, but advocates say it’s not enough - 12 months ago STAT+: More drug and device patents were invalidated for bad info than those filed by other industries, analysis finds - 12 months ago STAT+: Pharmalittle: FTC challenges ‘inaccurately or improperly’ listed patents; Elliott builds stake in BioMarin - about 1 year ago STAT+: FTC challenges several big drugmakers over inaccurate or improper patent listings - about 1 year ago STAT+: Pharmalittle: Vertex and U.K. at odds over value of CF meds; French authorities probe Sanofi over alleged market manipulation - about 1 year ago STAT+: Pharmalittle: Pharma trade group slams European Commission proposal; U.S. lawmakers demand FDA explain its approach to shortages - about 1 year ago STAT+: Pharmalittle: U.S. Senate eyes more policies for regulating PBMs; Novo claims most U.S. Wegovy patients pay less than $25 a month - about 1 year ago STAT+: Pharmalittle: Panel tells FDA that CRISPR sickle cell therapy is safe enough for patients; U.K. is urged to scrap IP demands in trade talks with India - about 1 year ago STAT+: Medicare is urged to consider Amgen patent maneuvers when negotiating the price for a drug - about 1 year ago STAT+: Pharmalittle: Pharma likely to expand legal attacks on Medicare negotiations; CDC recommends rationing RSV drug - about 1 year ago STAT+: Pharmalittle: People with obesity harmed by exclusion from studies; Teva sues Colorado over ‘unconstitutional’ program - about 1 year ago STAT+: Pharmalittle: Novo faces patent challenge on Wegovy and Ozempic; Senate panel moves to address drug shortages - about 1 year ago STAT+: Pharmalittle: More than 9 in 10 pharmacy techs report drug shortages; Yale and VA strike deal over ketamine patent royalties - about 1 year ago STAT+: Pharmalittle: Lilly sues spas and compounders over ‘unapproved’ Mounjaro; nasal-spray EpiPen alternative suffers setback - about 1 year ago STAT+: How a cash-prize system that phases out patents may lower drug prices - about 1 year ago
2	Torie Bosch STAT News Editor at STATNews. Hosts podcast. Pennsylvania opinionspodcasting	Opinion: STAT readers on hospital consolidation, patent system flaws, and asynchronous care - 20 days ago
3	N. Adam Brown MD MedPage Today Healthcare Strategist/Communicator. Washington, D.C. Healthcarestrategycommunication	Direct-to-Consumer Drugs: Big Pharma's Digital Health Play - 2 months ago
4	Amy Baxter Pharma Voice Scientist, inventor, former pediatrician. Atlanta, Georgia pain relieftechnologyinnovation	3 FDA approval dates to watch in the year’s final push - 2 months ago 3 Big Pharma cancer drugs facing inflation penalties - 4 months ago BMS’ long-standing leukemia blockbuster stares down its first generic - 4 months ago FDA’s platform designation aims to ease R&D pain points - 5 months ago
5	Meagan Parrish Pharma Voice Senior editor @industrydive. Pharma world follower. Wisconsin, USA pharmaceuticalsjournalismparenting	Is anyone taking the world’s priciest drugs? - 3 months ago After Vyvanse patent loss, Takeda’s neuroscience division looks to enter a new era - 6 months ago 3 recent FDA adcomm rejections — and why they matter - about 1 year ago
6	Meghana Keshavan STAT News Biotech nerd and writer @statnews. biotechwriting	Is pharma still fearful of the Inflation Reduction Act? - 3 months ago The biotech news you missed this week - 4 months ago
7	Beth Mole Ars Technica Senior Health Reporter @ArsTechnica. microbiologyinfectious diseasespublic health	Big Pharma’s fight against drug price reforms takes weird, desperate turn - 5 months ago Big Pharma spends billions more on executives and stockholders than on R&D - 9 months ago
8	Adam Feuerstein STAT News Reporter at STATnews. Dog lover. Polk Award winner. Boston, Massachusetts biotech reporting	A biotech’s binary bet ends badly - 5 months ago
9	Rachel Cohrs STAT News Washington Correspondent @statnews. Washington, DC health policyjournalism	STAT+: Pharma giants, government spar in court over Medicare drug price negotiation - 8 months ago STAT+: To lower drug prices, White House takes new aim at pharma patents - 11 months ago
10	Alexandra Pecci Pharma Voice Leading community for life sciences leaders. Washington, D.C. pharmaceuticalslife sciencescommunity building	How a 15-year-old Genzyme drug shortage became a legal smorgasbord of pharma’s thorniest issues - 9 months ago Government hits patent thickets on multiple fronts - 9 months ago 4 historic FDA approvals from 2023 - 11 months ago

Journalists covering drug patents